Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 92

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 92
---
| ● | the beneficial characteristics,                                            
 safety, efficacy and therapeutic effects of our future product candidates; |

| ● | our ability to obtain FDA                                                                                      
 approval for our GelrinC product and obtain and maintain regulatory approval of our future product candidates; |

| ● | our ability to obtain market                                                                                                    
 acceptance of our Gelrin hydrogel platform and any future product candidates from the medical community and third-party payors; |

| ● | our plans relating to the                                                                                               
 further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and                                              
 regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to                                                                                                                 
 obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing 
 the intellectual property rights of others;                                                                                              |

| ● | the need to hire additional                                     
 personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding                                                            
 expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third 
 parties;                |

| ● | our financial performance                     
 and our ability to repay our loans and debts; |

| ● | the period over which we                                                                                                         
 estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure 
 requirements;                                                                                                                    |

| ● | our ability to generate                                                                      
 revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties in our and                                                                                                          
 our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete 
 agreements with our physicians;                                                                                                  |

<div align='center'>56</div>

| ● | our ability to restructure                                             
 our operations to comply with future changes in government regulation; |

| ● | our ability to address                                                                                                            
 any competing technological and market developments that impact our Gelrin hydrogel platform and any future product candidates or 
 their prospective usage by medical professionals;                                                                                 |

| ● | our ability to negotiate                                                                                                             
 favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such 
 collaborations;                                                                                                                      |

| ● | our ability to maintain,                                                                                                              
 protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; |
| ● | our expectations regarding                                                                                                            
 having our Ordinary Shares listed on The Nasdaq Capital Market;